TY - JOUR
T1 - Inibitori dell’aromatasi nel trattamento dell’endometriosi profonda
AU - FERRERO, S.
AU - CAMERINI, G
AU - REMORGIDA, VALENTINO
PY - 2009
Y1 - 2009
N2 - Recent case reports and pilot studies suggested that aromatase inhibitors might be effective in treating pain symptoms related to the presence of endometriosis. We present the case of a 32-year-old woman who suffered dysmenorrhea, dyspareunia, chronic pelvic pain, and dyschezia caused by rectovaginal endometriosis. Pain symptoms recurred after treatment with the oral contraceptive pill; the patient refused surgery.Therefore a double-drug regimen including letrozole (2.5 mg/day) and norethisterone acetate (2.5 mg/day) was offered to the patient. The scheduled length of treatment was six months. This double-drug regimen determined a quick and significant improvement in all pain symptoms. During treatment, the patient complained mild arthralgia. After the interruption of treatment, pain symptoms quickly recurred and at 6-month follow-up their intensity was similar to baseline values. Operative laparoscopy was performed, the presence of rectovaginal endometriosis was confirmed and all visible endometriotic lesions were excised. Aromatase inhibitors might be offered when pain symptoms caused by endometriosis persist during the administration of other hormonal therapies and the patient refuses surgery. However, women must be informed that these drugs determine only a temporary relief of pain symptoms and might cause adverse effects (such as arthralgia).
AB - Recent case reports and pilot studies suggested that aromatase inhibitors might be effective in treating pain symptoms related to the presence of endometriosis. We present the case of a 32-year-old woman who suffered dysmenorrhea, dyspareunia, chronic pelvic pain, and dyschezia caused by rectovaginal endometriosis. Pain symptoms recurred after treatment with the oral contraceptive pill; the patient refused surgery.Therefore a double-drug regimen including letrozole (2.5 mg/day) and norethisterone acetate (2.5 mg/day) was offered to the patient. The scheduled length of treatment was six months. This double-drug regimen determined a quick and significant improvement in all pain symptoms. During treatment, the patient complained mild arthralgia. After the interruption of treatment, pain symptoms quickly recurred and at 6-month follow-up their intensity was similar to baseline values. Operative laparoscopy was performed, the presence of rectovaginal endometriosis was confirmed and all visible endometriotic lesions were excised. Aromatase inhibitors might be offered when pain symptoms caused by endometriosis persist during the administration of other hormonal therapies and the patient refuses surgery. However, women must be informed that these drugs determine only a temporary relief of pain symptoms and might cause adverse effects (such as arthralgia).
KW - Aromatase inhibitors
KW - endometriosis
KW - letrozole
KW - pain
KW - rectovaginal endometriosis
KW - Aromatase inhibitors
KW - endometriosis
KW - letrozole
KW - pain
KW - rectovaginal endometriosis
UR - https://iris.uniupo.it/handle/11579/118121
M3 - Article
SN - 1973-4832
VL - 3
SP - 103
EP - 108
JO - CLINICAL MANAGEMENT ISSUES
JF - CLINICAL MANAGEMENT ISSUES
ER -